Randomized Comparison of Combination Chemotherapy With Etoposide, Bleomycin, and Either High-Dose or Standard-Dose Cisplatin in Children and Adolescents With High-Risk Malignant Germ Cell Tumors: A Pediatric Intergroup Study—Pediatric Oncology Group 9049 and Children's Cancer Group 8882

Cushing, Barbara; Giller, Roger; Cullen, John W.; Marina, Neyssa; Lauer, Stephen J.; Olson, Thomas A.; Rogers, Paul C.; Colombani, Paul M.; Rescorla, Frederick J.; Billmire, Deborah F.; Vinocur, Charles D.; Hawkins, Edith P.; Davis, Mary M.; Perlman, Elizabeth J.; London, Wendy B.; Castleberry, Robert P.

doi:10.1200/jco.2004.08.015

Cited by 216 publications

(135 citation statements)

References 56 publications

Supporting

Mentioning

126

Contrasting

Unclassified

Order By: Relevance

“…CMP was added due to high response rates reported for single agent CNS treatment [30,31]. For nongerminomatous patients, the platinum dose was doubled based on data for systemic germ cell tumors, and for CNS nongerminomatous patients (86% survival after 400 mg/m 2 vs. 56% following 200 mg/m 2 ) [14,32]. The CMP dose was increased because of responses noted after single agent treatment in newly diagnosed and refractory disease [23].…”

Section: Discussionmentioning

confidence: 99%

Pre‐radiation chemotherapy with response‐based radiation therapy in children with central nervous system germ cell tumors: A report from the Children's Oncology Group

Kretschmar

Kleinberg

Greenberg

et al. 2007

Pediatric Blood & Cancer

106

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Pre‐radiation chemotherapy with response‐based radiation therapy in children with central nervous system germ cell tumors: A report from the Children's Oncology Group

Kretschmar

Kleinberg

Greenberg

et al. 2007

Pediatric Blood & Cancer

106

View full text Add to dashboard Cite

show abstract

“…[1][2][3][4][5][6][7][8] The rational design of multidrug protocols ideally follows a number of guidelines. 7 Each drug in the prescribed protocol should exhibit substantial activity as a single agent for the cancer in question.…”

mentioning

confidence: 99%

Impact of Chemotherapeutic Dose Intensity and Hematologic Toxicity on First Remission Duration in Dogs with Lymphoma Treated with a Chemoradiotherapy Protocol

Vaughan

Johnson

Williams

2007

Veterinary Internal Medicne

View full text Add to dashboard Cite

Background: Dose intensity has proven to be critical in maximizing chemotherapeutic efficacy for numerous human cancers. To date, the impact of dose intensity and toxicity on first remission duration has not been thoroughly assessed in dogs with lymphoma.Hypothesis: Dogs that receive maximal dose intensity will have prolonged first remission duration. Animals: Sixty-two dogs with lymphoma that were treated according to a standardized chemoradiotherapy regimen and achieved durable complete remissions were identified from the medical records database of North Carolina State University.Methods: Dosage reductions and treatment delays resulting from chemotherapy-related neutropenia were evaluated retrospectively, and each patient's actual summation dose intensity and frequency of myelotoxicity were calculated. Impact of dose intensity and frequency of neutropenia on first remission duration were evaluated by Cox proportional hazards regression.Results: Development of grade III or IV neutropenia during chemotherapy was found to be associated with prolonged first remission duration (P , .01). Dose intensity did not have a significant impact on remission duration (P 5 .07).Conclusions and Clinical Importance: Results of this study suggest that dosage reductions and treatment delays instituted to avoid repeated neutropenic episodes do not reduce first remission duration. Prolonged remission duration in patients that developed grade III or IV neutropenic episodes indicates the need for further optimization of dosing strategies for canine lymphoma patients undergoing chemotherapy.

show abstract

“…High-dose chemotherapy is currently investigated as a possible option for high-risk and recurrent CNS GCTs, and is used on an individual basis as salvage therapy for children with other extragonadal germ-cell malignancies (Calaminus and Patte, 2002;Cushing et al, 2004;Kellie et al, 2004;Modak et al, 2004). Few series with salvage chemotherapy for relapse GCT patients with extragonadal primary are reported in literature.…”

Section: Discussionmentioning

confidence: 99%

“…The overall survival has been similar in both regimens; treatment-related deaths and grade 3 -4 toxicities have been more common with HDC. As a consequence, the arm including high-dose cisplatin is not being recommend for paediatric patients as first-line treatment (Cushing et al, 2004).…”

Section: Discussionmentioning

confidence: 99%

Salvage high-dose chemotherapy for children with extragonadal germ-cell tumours

et al. 2005

View full text Add to dashboard Cite

We reviewed the European Group for Blood and Marrow Transplantation (EBMT) experience with salvage high-dose chemotherapy (HDC) in paediatric patients with extragonadal germ-cell tumour (GCT). A total of 23 children with extragonadal GCT, median age 12 years (range 1 -20), were treated with salvage HDC with haematopoietic progenitor cell support. The GCT primary location was intracranial site in nine cases, sacrococcyx in eight, retroperitoneum in four, and mediastinum in two. In all, 22 patients had a nongerminomatous GCT and one germinoma. Nine patients received HDC in first-and 14 in second-or third-relapse situation. No toxic deaths occurred. Overall, 16 of 23 patients (70%) achieved a complete remission. With a median follow-up of 66 months (range 31 -173 months), 10 (43%) are continuously disease-free. Of six patients who had a disease recurrence after HDC, one achieved a disease-free status with surgical resection followed by chemotherapy and radiotherapy. In total, 11 patients (48%) are currently disease-free. Eight of 14 patients (57%) with extracranial primary and three of nine patients (33%) with intracranial primary GCT are currently disease-free. HDC induced impressive long-term remissions as salvage treatment in children with extragonadal extracranial GCTs. Salvage HDC should be investigated in prospective trials in these patients.

show abstract

Randomized Comparison of Combination Chemotherapy With Etoposide, Bleomycin, and Either High-Dose or Standard-Dose Cisplatin in Children and Adolescents With High-Risk Malignant Germ Cell Tumors: A Pediatric Intergroup Study—Pediatric Oncology Group 9049 and Children's Cancer Group 8882

Abstract: Combination chemotherapy with HDPEB significantly improves EFS for children with high-risk MGCT. The OS is similar in both regimens, and the significant toxicity associated with HDPEB limits its use.

Cited by 216 publications

References 56 publications

Pre‐radiation chemotherapy with response‐based radiation therapy in children with central nervous system germ cell tumors: A report from the Children's Oncology Group

Pre‐radiation chemotherapy with response‐based radiation therapy in children with central nervous system germ cell tumors: A report from the Children's Oncology Group

Impact of Chemotherapeutic Dose Intensity and Hematologic Toxicity on First Remission Duration in Dogs with Lymphoma Treated with a Chemoradiotherapy Protocol

Salvage high-dose chemotherapy for children with extragonadal germ-cell tumours

Contact Info

Product

Resources

About